41
Participants
Start Date
June 24, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
CMTX-101
CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
Placebo
Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
Lenox Hill Hospital, New York
New York Medical College, Hawthorne
UPMC Children's Hospital of Pittsburgh, Pittsburgh
PennState Health, Hershey
University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
Virginia Commonwealth University, Richmond
Medical University of South Carolina, Charleston
Central Florida Pulmonary Group, PA, Orlando
University of Alabama, Birmingham, Birmingham
Vanderbilt University, Nashville
Nationwide Children's Hospital, Columbus
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland
University of Michigan, Ann Arbor
Cystic Fibrosis Institute, Northfield
University of Kansas, Kansas City
National Jewish Health, Denver
St Luke's Sleep Medicine and Research Center, Boise
University of Utah, Salt Lake City
University of California, San Francisco, San Franciso
Stanford University, Palo Alto
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
Lead Sponsor
Clarametyx Biosciences, Inc.
INDUSTRY